Correlation between hepatitis B virus genotypes and clinical outcomes

Japanese Journal of Infectious Diseases

Volumn 65, Issue 6, 2012, Pages 476-482

  Shi, Ying Hui ^a  

^a Qingdao YH Virus Institute   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ENTECAVIR; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; TENOFOVIR; VIRUS DNA;

AGE; ALOPECIA; ANOREXIA; ANTIVIRAL THERAPY; BONE MARROW SUPPRESSION; CANCER RISK; DEPRESSION; DRUG EFFICACY; DRUG INDUCED HEADACHE; FATIGUE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENE MUTATION; GENETIC VARIABILITY; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INJECTION SITE REACTION; INSOMNIA; IRRITABILITY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MENTAL DISEASE; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; REVIEW; SEROCONVERSION; SIDE EFFECT; THYROID DISEASE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS INHIBITION; VIRUS REPLICATION; VIRUS TYPING; WEIGHT REDUCTION;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; GENOTYPE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; LIVER NEOPLASMS; TREATMENT OUTCOME; VIRAL LOAD; VIRULENCE;

EID: 84869821677     PISSN: 13446304     EISSN: 18842836     Source Type: Journal    
DOI: 10.7883/yoken.65.476     Document Type: Review

References (71)

1. Lai, C.-L., Ratziu, V., Yuen, M.-F., et al. (2003): Viral hepatitis B. Lancet, 362, 2089-2094.
2. Custer, B., Sullivan, S.-D., Hazlet, T.-K., et al. (2004): Global epidemiology of hepatitis B virus. J. Clin. Gastroenterol., 38, S158-S168.
3. Lindh, M., Andersson, A.-S. and Gusdal, A. (1997): Genotypes, nt1858 variants, and geographic origin of hepatitis B virus-largescale analysis using a new genotyping method. J. Infect. Dis., 175, 1285-1293.
4. Beasley, R.-P., Trepo, C., Stevens, C.-E., et al. (1977): The e antigen and vertical transmission of hepatitis B surface antigen. Am. J. Epidemiol., 105, 94-98.
5. Wong, S.-N. and Lok, A.-S. (2006): Treatment of hepatitis B: who, when, and how? Arch. Intern. Med., 166, 9-12.
6. Ganem, D. and Varmus, H.-E. (1987): The molecular biology of the hepatitis B viruses. Annu. Rev. Biochem., 56, 651-693.
7. Courouce-Pauty, A.-M., Plancon, A. and Soulier, J.-P. (1983): Distribution of HBsAg subtypes in the world. Vox. Sanguinis, 44, 197-211.
8. Okamoto, H., Tsuda, F., Sakugawa, H., et al. (1988): Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J. Gen. Virol., 69, 2575-2583.
9. Fang, Z.-L., Zhuang, H., Wang, X.-M., et al. (2004): Hepatitis B virus genotypes, phylogeny and occult infection in a region with a high incidence of hepatocellular carcinoma in China. World J. Gastroenterol., 10, 3264-3268.
10. Cao, G.-W. (2009): Clinical relevance and public health significance of hepatitis B virus genomic variations. World J. Gastroenterol., 22, 37-44.
11. Kurbanov, F., Tanaka, Y. and Mizokami, M. (2010): Geographical and genetic diversity of the human hepatitis B virus. Hepatol. Res., 40, 14-30.
12. Thedja, M.-D., Muljono, D.-H., Nuraiy, N., et al. (2011): Ethnogeographical structure of hepatitis B virus genotype distribution in Indonesia and discovery of a new subgeotype, B9. Arch. Virol., 156, 855-868.
13. Chekaraou, M,-A., Brichler, S., Mansour, W., et al. (2010): A novel hepatitis B virus (HBV) sub-genotype D (D8) strain, resulting from recombination between genotypes D and E, is circulating in Niger along with HBV/E strains. J. Gen. Virol., 91, 1609-1620.
14. Arauz-Ruiz, P., Norder, H., Robertson, B.-H., et al. (2002): Genotype H: a new Amerindian genotype of hepatitis B virus related in Central America. J. Gen. Virol., 83, 2059-2073.
15. Tran, T.-T., Trinh, T.-N. and Abe, K. (2008): New complex recombinant genotype of hepatitis B virus identified in Vietnam. J. Virol., 34, 592-594.
16. Thuy, P.-T., Alestig, E., Liem, N.-T., et al. (2010): Genotype X/C recombinant (putative genotype I) of hepatitis B virus is rare in Hanoi, Vietnam-genotypes B4 and C1 predominate. J. Med. Virol., 82, 1327-1333.
17. Tatematsu, K., Tanaka, Y., Kurbanov, F., et al. (2009): A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and previsionally assigned to new genotype J. J. Virol., 83, 10538-10547.
18. Mulyanto, Depamede, S.-N., Wahyono, A., et al. (2011): Analysis of the full-length genomes of novel hepatitis B virus subgenotpes C11 and C12 in Papua, Indonesia. J. Med. Virol., 83, 54-64.
19. Mulyanto, Pancawardsni, P., Depanmede, S.-N., et al. (2012): Identification of four novel subgenotypes (C13-C16) and two inter-genotypic recombinants (C12/G and C13/B3) of hepatitis B virus in Papua province, Indonesia. Virus Res., 163, 129-140.
20. Baig, S., Siddiqui, A.-A., Ahmed, A., et al. (2007): The association of complex liver disorders with HBV genotypes prevalent in Pakistan. Virol. J., 4, 128.
21. Sugauchi, F., Mizokami, M., Orito, E., et al. (2001): A novel variant genotype C of hepatitis B virus identified in isolates from Australian Aborigines: complete genome sequence and phylogenetic relatedness. J. Gen. Virol., 82, 883-892.
22. Kao, J.-H. (2011): Molecular epidemiology of hepatitis B virus. Korean J. Intern. Med., 26, 255-261.
23. Yuasa, R., Takahashi, K., Dien, B.-V., et al. (2000): Properties of hepatitis B virus genome recovered from Vietnamese patients with fulminant hepatitis in comparison with those of acute hepatitis. J. Med. Virol., 61, 23-28.
24. Karin, K.-L., Myhre, E., Blackberg, J., et al. (2004): Clinical and serologicl variation between patients infected with different hepatitis B virus genotypes. J. Clin. Microbiol., 42, 5837-5841.
25. Victoria, F.-S., deOliverira, C.-M., Victoria, M.-B., et al. (2008): Characterization of HBeAg-negative chronic hepatitis B in Western Brazilian Amazonia. Brazil. J. Infect. Dis., 12, 27-37.
26. Imamura, T., Yokosuka, O., Kurihara, T., et al. (2003): Distribution of hepatitis B viral genotypes and mutations in the core promoter and precore regions in acute forms of liver disease in patients from Chiba, Japan. Gut, 52, 1630-1637.
27. Maeshiro, T., Arakaki, S., Watanabe, T., et al. (2007): Different natural course of chronic hepatitis B with genotypes B and C after the fourth decade of life. World J. Gastroenterol., 13, 4560-4565.
28. Tonetto, D.-A., Goncakes, N.-S., Fais, V.-C., et al. (2009): Hepatitis B virus: molecular genotypes and HBeAg serological status among HBV-infected patients in the southeast of Brazil. BMC Infect. Dis., 9, 149.
29. Mojiri, A., Abbas, B.-B., Saberifirozi, M., et al. (2008): Hepatitis B virus genotypes in Southwest Iran: molecular, serological and clinical outcomes. World J. Gastroenterol., 14, 1510-1513.
30. Ribeiro, R.-M., Germanidis, G., Power, K.-A., et al. (2010): Hepatitis B virus kinetics under antiviral therapy sheds light on differences in hepatitis B e antigen positive and negative infections. J. Infect. Dis., 202, 1309-1317.
31. Valsamakis, A. (2007): Molecular testing in the diagnosis and management of chronic hepatitis B. Clin. Microbiol. Rev., 20, 426-439.
32. Furusyo, N., Nakashima, H., Kashiwagi, K., et al. (2002): Clinical outcomes of hepatitis B virus (HBV) genotype B and C in Japanese patients with chronic HBV infection. Am. J. Trop. Med. Hyg., 67, 151-157.
33. Kao, J.-H., Chen, P.-J., Lai, M.-Y., et al. (2002): Genotypes and clinical phenotypes of hepatitis B virus in patients with chronic hepatitis B virus infection. J. Clin. Microbiol., 40, 1207-1209.
34. Yu, M.-W., Yeh, S.-H., Chen, P.-J., et al. (2005): Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: A prospective study in men. J. Natl. Cancer Inst., 97, 265-272.
35. Chen, C.H., Lee, C.-M., Lai, S.-N., et al. (2005): Clinical significance of hepatitis B virus (HBV) genotypes and precore and core promoter mutations affecting HBV e antigen expression in Taiwan. J. Clin. Microbiol., 43, 6000-6006.
36. Orito, E., Mizokami, M., Sakugawa, H., et al. (2002): A casecontrol study for clinical and molecular biological differences between hepatitis B viruses of genotype B and C. Hepatology, 33, 218-223.
37. Kuang, S.-Y., Jackson, P.-E., Wang, J.-B., et al. (2004): Specific mutations of hepatitis B virus in plasma predict liver cancer development. Proc. Natl. Acad. Sci. USA, 101, 3575-3580.
38. Lusida, M.-I., Nugrahaputra, V.-E., Soetjipto., et al. (2008): Novel subtypes of hepatitis B virus genotypes C and D in Papua, Indonesia. J. Clin. Microbiol., 46, 2160-2166.
39. Kao, J.H., Chen, P.J., Lai, M.Y., et al. (2003): Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology, 124, 327-334.
40. Fujie, H., Moriya, K., Shintani, Y., et al. (2001): Hepatitis B virus genotypes and hepatocellular carcinoma in Japan. Gastroenterology, 120, 1564-1565.
41. Kao, J.-H., Chen, P.-I, Liaw, Y.-F., et al. (2001): Hepatitis B genotype correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology, 118, 554-559.
42. Sugauchi, F., Kumada, H., Sakugawa, H., et al. (2004): Two subtypes of genotype B (Ba and Bj) of hepatitis B virus in Japan. Clin. Infect. Dis., 38, 1222-1228.
43. Wang, Z., Tanaka, Y., Huang, Y., et al. (2007): Clinical and virological characteristics of hepatitis B virus subgenotypes Ba, C1, and C2 in China. J. Clin. Microbiol., 45, 1491-1496.
44. Akuta, N. and Kumada, H. (2005): Influence of hepatitis B virus genotype on the response to antiviral therapies. J. Antimicrobiol. Chem., 55, 139-142.
45. Buster, E.H.C.J. and Janssen, H.L.A. (2006): Antiviral treatment for chronic hepatitis B virus infection-immune modulation or viral suppression? Netherlands J. Med., 64, 175-185.
46. Haria, M. and Benfield, P. (1995): Interferon-alpha-2a: a review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Drugs, 30, 873-896.
47. Kao, J.H., Wu, N.H., Chen, P.S., et al. (2000): Hepatitis B genotypes and response to interferon therapy. J. Hepatol., 33, 998-1002.
48. Wai, C.-T., Chu, C.-S., Hussain, M., et al. (2002): HBV genotype B is associated with better response to interferon therapy in HBeAg (+) chronic hepatitis than genotype C. Hepatology, 36, 1425-1430.
49. Ma, J.-C., Wang, L.-W., Li, X.-J., et al. (2007): Relationship between HBV genotypes and antiviral therapeutic efficacy of interferon-alpha. Hepatobiliary Pancreat' Dis. Int., 6, 166-171.
50. Craxi, A. and Cooksley, W.-G. (2003): Pegylated interferon for chronic hepatitis B virus. Antiviral. Res., 60, 87-89.
51. Cooksley, W.-G., Piratvisuth, T., Lee, S.-D., et al. (2003): Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J. Virol. Hepat., 10, 298-305.
52. Janssen, H.-L., vanIonneveld, M., Senturk. H., et al. (2005): Peglated interferon alpha-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomized trial. Lancet, 365, 123-129.
53. Flink, H.-J, van Zonneveld, M., Hansen, B.-E., et al. (2006): Treatment with Peg-interferon a-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am. J. Gastroenterol., 101, 297-303.
54. Jassen, H.-L., Berk, L., Vermeulen, M., et al. (1990): Seizures associated with low-dose alpha-interferon. Lancet, 336, 1580.
55. Yao, F.-Y. and Bass, N.-M. (2000): Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J. Hepatol., 33, 301-307.
56. Yao, F.-Y., Terrault, N.-A., Freise, C., et al. (2001): Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating hepatitis B infection awaiting liver transplantation: a comparative study using a matched, untreated cohort. Hepatology, 34, 411-416.
57. Moskoviz, D.-N., Osiowy, C., Giles, E., et al. (2005): Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance. J. Virol. Hepat., 12, 398-404.
58. Kapoor, D., Guptan, R.-C., Wakil, S.-M., et al. (2000): Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J. Hepatol., 33, 308-312.
59. Liaw, Y.-F., Leung, N.-W., Chang, T.-T., et al. (2000): Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology, 119, 172-180.
60. Yuen, M.-F., Wong, D.-K., Sablon, E., et al. (2003): Hepatitis B virus genotype B and C do not affect the antiviral response to lamivudine. Antivir. Ther., 8, 531-534.
61. Wang, G.-Y., Zhu, W.-J., Yang, X.-L., et al. (2005): YMDD mutation of hepatitis B virus and genotyping in Guiyang region. Chin. J. Hepatol., 13, 193-195 (in Chinese).
62. Akuta, N., Suzuki, F., Kobayashi, M., et al. (2003): The influence of hepatitis B virus genotype on the development of lamivudine resistance during long-term treatment. J. Hepatol., 38, 315-321.
63. Rizzetto, M., Tassopoulos, N.-C., Goldin, R.-D., et al. (2005): Extended lamivudine treatment in patients with HBeAg-negative chronic hepatitis B. J. Hepatol., 42, 173-179.
64. Brunetto, M.-A. and Bonino, F. (2004): Treatment of chronic hepatitis B: from research to clinical practice via the consensus conferences. Curr. Pharm. Des., 10, 2063-2075.
65. Kao, J.-H., Liu, C.-J. and Chen, D.-S. (2002): Hepatitis B viral genotypes and lamivudine resistance. J. Hepatol., 36, 303-304.
66. Nagasaki, F., Niitsuma, H., Ueno, Y., et al. (2007): The high incidence of the emergence of entecavir-resistant mutants among patients infected with lamivudine-resistant hepatitis B virus. Tohoku J. Exp. Med., 213, 181-186.
67. Lagget, M. and Rizzetto, M. (2003): Current pharmacotherapy for the treatment of chronic hepatitis B. Expert. Opin. Pharmacother., 4, 1821-1827.
68. Economou, M., Manolakopoulos, S., Trikalinos, T.-A., et al. (2005): Interferon-a plus lamivudine vs lamivudine reduces breakthroughs, but does not affect sustained response in HBeAg negative chronic hepatitis B. World J. Gastroenterol., 11, 5882-5887.
69. Schlaak, J.-F., Tully, G., Loä hr, H.-F., et al. (1999): HBV-specific immune defect in chronic hepatitis B (CHB) is correlated with a dysregulation of pro-and anti-inflammatory cytokines. Clin. Exp. Immunol., 115, 508-514.
70. Milich, D.-R., Peterson, D.-L., Schoä del, F., et al. (1995): Preferential recognition of hepatitis B nucleocapsid antigens by Th1 or Th2 cells is epitope and major histocompatibility complex dependent. J. Virol., 69, 2776-2785.
71. Shi, Y.-H. and Shi, C.-H. (2009): Molecular characteristics and stages of chronic hepatitis B virus infection. World J. Gastroenterol., 15, 3099-3105.